针对上述提问，贝达药业回应称："您好！公司港股上市发行相关工作正有序推进中，如有下一步重大 进展将及时公告披露。公司一贯重视与合作伙伴的协作关系，目前双方已就里程碑付款进行相关的沟通 和交流，会妥善解决。谢谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向贝达药业提问："你好董秘 市场有传言因为益方生物应付款问题，公司遭到港交 所问询，被驳回上市请求。请董秘辟谣，或予以证实。" 本文源自：市场资讯 作者：公告君 ...

证券日报网讯 1月15日，贝达药业在互动平台回答投资者提问时表示，公司通过自主研发或与领先的第 三方AI平台合作，将人工智能应用于靶点发现和评估、耐药机制识别及真实世界数据的机器学习等， 从而赋能早期药物研发与临床研究，助力提升研发效率。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 1月15日，贝达药业在互动平台回答投资者提问时表示，杭州知兴制药有限公司专注于高 端吸入制剂研发与生产，核心技术人员行业背景深厚，已搭建完善的研发与生产体系，具备将产品从实 验室到产业化落地的能力。公司投资知兴制药，布局高端吸入制剂领域，符合公司长期发展战略，双方 围绕创新研发、技术平台等领域开展深度合作，有助于拓展公司新药创制技术平台，进一步拓宽疾病治 疗领域的战略布局。 ...

Core Insights - Bidda Pharmaceutical has signed a strategic cooperation agreement with Westlake University to focus on life sciences and pharmaceutical innovation, emphasizing student training, technological breakthroughs, platform construction, and achievement transformation [1][2] - The collaboration aims to enhance the entire chain from basic research to industrial application, reflecting the growing innovation environment in Hangzhou [1] Group 1: Company Initiatives - Bidda Pharmaceutical is a leading domestic innovative drug company that has established four funds to incubate nearly 30 cutting-edge projects across various fields, including small molecules, antibodies, gene/cell therapy, and CDMO [1] - The "Bidda Innovation Ecosystem Alliance" was established at the ninth Wanwu Growth Conference, aiming to integrate resources from industry, academia, research, healthcare, and investment to enhance collaborative efficiency [1] Group 2: Project Developments - The RGB-5088 pancreatic cell injection project, part of the ecosystem, received approval from the National Medical Products Administration to enter clinical trials on December 6, 2024, showcasing the ecosystem's ability to accelerate early-stage original projects [1] Group 3: Industry Environment - Hangzhou has implemented numerous supportive policies for innovative drugs and medical devices, creating a conducive environment for entrepreneurship and innovation [1] - The Yangtze River Delta Biopharmaceutical Industry Development Conference held in December last year fostered a consensus on collaboration among capital, technology, and industry, providing a broad platform for university-enterprise cooperation and achievement transformation [1]

Group 1 - The core point of the article highlights that BeiGene's stock closed at 51.42 yuan, with a slight increase of 0.76% on January 14 [1] - A significant block trade occurred, involving a total of 144,700 shares and a transaction amount of 5.9067 million yuan, with a transaction price of 40.82 yuan per share, reflecting a discount of 20.61% [1] - Over the past three months, the stock has seen a total of 9 block trades, accumulating a transaction amount of 43.6933 million yuan [1] Group 2 - In the last five trading days, the stock has increased by 3.71%, while the net outflow of main funds amounted to 45.7447 million yuan [1]

Core Viewpoint - The company is progressing with its Hong Kong listing application and is currently operating normally with stable cash flow [2] Group 1 - The company is actively responding to investor inquiries regarding its operations and listing status [2] - The application for the Hong Kong listing is being carried out in an orderly manner [2] - The company's current operational status is stable, indicating a healthy cash flow situation [2]

Core Viewpoint - The company emphasizes the importance of strategic partnerships and is actively seeking diverse collaboration opportunities with leading global biopharmaceutical firms, promising to disclose any significant developments in a timely manner [1] Group 1 - The company is focused on strategic cooperation and is engaging with top global biopharmaceutical companies [1] - The company is exploring various collaboration methods to enhance its strategic partnerships [1] - The company commits to timely announcements regarding any major progress in its partnerships [1]

Core Viewpoint - The company emphasizes its commitment to legal compliance and timely information disclosure in response to investor inquiries [1] Group 1 - The company stated that it adheres to laws, regulations, and exchange rules regarding information disclosure [1] - The establishment of wholly-owned subsidiaries is considered a routine business operation and does not fall under mandatory disclosure requirements [1]

Group 1 - The company, BeiGene, submitted an application for the issuance of overseas listed shares (H shares) and for listing on the Hong Kong Stock Exchange on September 29, 2025 [2] - The application materials for this issuance and listing were published on the Hong Kong Stock Exchange's website on the same day [2] - The related work for the Hong Kong stock listing is progressing in an orderly manner, and the company will announce any significant developments in a timely manner [2]

Group 1 - The core concern raised by investors is about the potential delay in the listing of MCLA-129, suggesting that if it is not submitted soon, the competitive landscape may diminish significantly [2] - Beida Pharmaceutical (300558.SZ) has responded that the clinical trial work for MCLA-129 is progressing in an orderly manner and that the company will announce any significant developments in a timely manner [2]